Background:Sino‐nasal mucormycosis is an opportunistic, invasive fungal disease which has shown a rising trend in the setting of COVID‐19. The objective of this study is to document and analyze demographic data, clinical presenta‐ tion and MR imaging spectra for early detection and management of post‐COVID‐19 sino‐nasal mucormycosis. Results:Sixty‐two cases of sino‐nasal mucormycosis were enrolled in this study; their mean age was50.65 ± 8.25 years, with significant female predominance. Nine patients (14.5%) had active COVID‐19 and 53 (85.5%) were recent COVID‐19 cases. Sixty patients have not received COVID‐19 vaccine. The mean duration from the initial COVID‐19 laboratory confirmation to the detection of sino‐nasal mucormycosis was 25.7 +/− 4.6 days. Thirty‐five patients (56.5%) were kept in the hospital for COVID management and 4 of them received intensive care unit (ICU) treatment. Twenty‐seven patients (43.5%) were treated in home isolation. Corticosteroids were administered in 48 cases (77.4%). Twenty‐nine patients (46.8%) had been given oxygen for an average time of 11.2 ± 4.15 days. Diabetes was found in 56 cases (90.3%). The most common clinical symptoms were headache, seen in 52 patients (83.87%). The ethmoid sinus was the most common paranasal sinus involved in our study, seen in 47 cases (75.81%). In 36 cases (58%), multiple sinuses were involved. MRI staging according to the extent of regional involvement. Stage 1 seen in 2 cases (3.23%), stage 2 in 13 cases (20.97%), stage 3 in 35 cases (56.45%) and stage 4 in 12 cases (19.35%). Conclusions:MRI shows a spectrum of findings in sino‐nasal mucormycosis. Imaging plays a major role in staging and assessing the extent of involvement and complications. In light of this, mortality and morbidity can be dramati‐ cally decreased with adequate evaluation and therapy.